Some businesses are now backtracking on DEI. Biopharma cannot afford to and must remain resolute
?w=2048
'Leaders must hold the line so that never again are medicines developed for and by only some of us,' writes Cytokinetics CEO Robert Blum.
Discussion
No replies yet.